E
Encompass Health Corporation
EHC · Healthcare
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 15, 2026
A Quality Toll Road Priced Like the Tollbooth Might Disappear
Most investors see aging demographics and stop thinking; the more interesting question is whether Encompass's documented superior outcomes data — 84.6% discharge-to-community rate — is quietly building the value-based care argument that makes IRF reimbursement *more* defensible precisely as CMS scrutinizes it, turning the regulatory threat into a long-term moat expansion opportunity. The market is pricing the threat; it is not pricing the response.
Flowly Score
Apr 16 Close
+56%$105.49
Fair Value
$165.00
66
Strongat $105.49
Business Strength7/10
A genuine regulatory and scale moat — CON laws, the 60% rule, and JV referral lock-in do real competitive work — but the federal government sets every price, which permanently caps the ceiling on moat quality. Improving ROIC and disciplined capital allocation from management that chose focus over empire-building earns real credit.
Financial Resilience7/10
Cash conversion is textbook — OCF reliably clears net income every year, driven by the non-cash depreciation load on a fixed-asset-heavy hospital network, not accounting creativity. The Altman Z in the gray zone is the one flag worth watching, but rapidly declining leverage and accelerating free cash flow suggest the trajectory matters more than the snapshot.
Growth & Trajectory7/10
Revenue compounding with earnings growing materially faster is operating leverage working exactly as intended, and the small-format 24-bed hospital model opening in 2027 unlocks a hub-and-spoke expansion that the current network cannot access. The VA program growing at over 20% quarterly is an underappreciated diversification that almost nobody is modeling into forward estimates.
Valuation7/10at $100.37
An EV/EBITDA multiple sitting well below the business's own historical range, on a business with accelerating cash generation and improving returns — that combination is unusual and suggests the market is pricing in regulatory disruption that hasn't materialized. The neutral DCF alone implies substantial upside, and the multiples compression happened while fundamentals were actually getting better.
Risk4/10
The single-payer concentration risk here is not abstract — Washington literally owns the pricing mechanism for the entire business model, and any serious deficit reduction agenda will target the IRF reimbursement premium over skilled nursing alternatives. The TEAM model affecting 89 hospitals, RCD rollout in large states, and the theoretical technology disruption from AI-guided home rehabilitation are real headwinds stacked on top of that structural vulnerability.
Encompass Health is a rare combination: a capital-intensive regulated business with genuine structural barriers, trading at a discount to intrinsic value on improving fundamentals. The regulatory moat — CON laws in half the country, the 60% clinical threshold, and JV ownership stakes that make referring hospitals partners rather than customers — is more durable than the market's current multiple implies. ROIC has expanded meaningfully over five years while the company was actively building new hospitals, which is the proof that growth spending is genuinely value-creating rather than treadmill capital. The earnings yield and EV/EBITDA are both sitting at levels more consistent with a business under stress than one generating record cash flow and guiding confidently for another strong year. The trajectory here is quietly inflecting in ways the consensus is slow to recognize. The small-format 24-bed hospital concept beginning in 2027 unlocks dense urban markets where a 60-bed flagship cannot be sited — this is a genuine TAM expansion, not a marketing repackage. VA referrals growing at over 20% per quarter represent a payer diversification that reduces Medicare concentration risk precisely when that concentration looks most threatening. And labor cost normalization — contract labor now at its lowest share since early 2021 — is releasing margin that was buried in the income statement for three years, making the operating leverage story more visible than it has been. The single risk that keeps this from being a straightforward conviction position is a CMS site-neutral payment rule that collapses the reimbursement premium IRFs command over skilled nursing facilities. This is not a tail risk — it is an active policy discussion in every budget negotiation cycle. If Washington decides that post-acute settings should be paid equivalently regardless of clinical intensity, the economics of every incremental hospital build deteriorate overnight, the JV model loses its appeal to health system partners, and the entire reinvestment thesis needs rebuilding from scratch. That risk is priced in somewhat at current levels, but it cannot be dismissed.